Cougar Biotechnology Initiates Phase III Trial Of CB7630 (Abiraterone Acetate) In Chemotherapy-Naïve Castration-Resistant Prostate Cancer Patients

Main Category: Prostate / Prostate Cancer
Also Included In: Cancer / Oncology;  Clinical Trials / Drug Trials
Article Date: 04 May 2009 - 0:00 PDT

email to a friend   printer friendly   opinions  

Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced the initiation of a Phase III clinical trial (COU-AA-302) of its lead drug candidate CB7630 (abiraterone acetate) in patients with chemotherapy-naïve castration-resistant prostate cancer (CRPC). The COU-AA-302 Phase III trial is a randomized, double-blind, placebo-controlled trial of CB7630 plus prednisone in patients with metastatic CRPC who have not yet received treatment with chemotherapy. The trial is expected to enroll approximately 1,000 patients who will be randomized (1:1) to receive either CB7630 plus prednisone or placebo plus prednisone. The trial will be conducted at approximately 150 sites in North America, Europe and Australia. The co-primary endpoints of the trial are progression free survival and overall survival. The Company plans to use the progression free survival data from the trial as the basis for submission of a New Drug Application and a Marketing Authorization Application for Accelerated and Conditional Approval from the regulatory agencies.

Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology, said, "Initiation of this Phase III trial of CB7630 in chemotherapy-naïve prostate cancer patients represents an important milestone in the clinical development of CB7630. As these patients continue to represent a market that is underserved with current treatments, we are pleased to initiate the COU-AA-302 Phase III trial in this patient population."

Arturo Molina, M.D., M.S., FACP, Chief Medical Officer and Executive Vice President of Clinical Research and Development of Cougar, added, "The interim results of our Phase II trials of CB7630 have shown strong evidence of antitumor activity in patients with metastatic CRPC who have not yet received chemotherapy; therefore, we are pleased to initiate the COU-AA-302 Phase III trial in this patient population. Due to the high level of awareness of CB7630 in the urology and medical oncology communities, we look forward to aggressively enrolling this Phase III trial."

Source
Cougar Biotechnology

• Additional
• References
• Citations